Arrhythmia drug may increase cancer risk

One of the most widely used medications to treat arrhythmias may increase the risk of developing cancer, especially in men and people exposed to high amounts of the drug. That is the conclusion of a new retrospective study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The study's results indicate that a potential link between amiodarone and cancer warrants further investigation.

Amiodarone was approved in 1985 for the treatment of arrhythmias, or . Because the drug is fat-soluble and degrades very slowly, large amounts can accumulate in soft tissues after a long-term prescription. Previous studies have shown that amiodarone might increase the risk of certain cancers, but no large-scale study has looked at the issue.

To investigate, Vincent Yi-Fong Su, MD, of the Taipei Veterans General Hospital in Taiwan, and his colleagues studied 6,418 individuals taking the drug, following them for an average of 2.57 years. A total of 280 participants developed cancer.

Patients who were male or who received high cumulative daily doses of amiodarone within the first year had an increased risk of developing cancer. Those with both factors were 46 percent more likely to develop cancer than those with neither factor. After taking age, sex, and illnesses into account, individuals taking a high amount of amiodarone had nearly twice the risk of developing cancer as those taking a low amount of the drug.

"We suggest that cancer events should be routinely reported in future amiodarone trials, and further observational research is necessary," said Dr. Su. "Also, when prescribing amiodarone, doctors need to keep in mind that this medication may increase ."

More information: "Amiodarone and the risk of cancer: A nationwide population-based study." Vincent Yi-Fong Su, Yu-Wen Hu, Kun-Ta Chou, Shuo-Ming Ou, Yu-Chin Lee, Elizabeth Ya-Hsuan Lin, Tzeng-Ji Chen, Cheng-Hwai Tzeng, and Chia-Jen Liu. Cancer; Published Online: April 8, 2013 DOI: 10.1002/cncr.27881

Related Stories

Common diabetes drug may help treat ovarian cancer

Dec 03, 2012

A new study suggests that the common diabetes medication metformin may be considered for use in the prevention or treatment of ovarian cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer ...

Recommended for you

Endogenous hormones improve breast cancer risk models

19 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

20 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments